deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02738008

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Sponsor: Arrowhead Pharmaceuticals

Conditions Hepatitis B
Interventions ARC-520 Injection antihistamine entecavir tenofovir
Updated 11 times since 2017 Last updated: Dec 19, 2025 Started: Mar 31, 2016 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company decision to discontinue trial

Other terminated trials from Arrowhead Pharmaceuticals

See all terminations from Arrowhead Pharmaceuticals

Other Hepatitis B trials with similar outcome

Browse all Hepatitis B trials

A PHASE2 clinical study on Hepatitis B, this trial is terminated or withdrawn. The trial is conducted by Arrowhead Pharmaceuticals and has accumulated 11 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotTerminated~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotTerminated~Jun 2018 – ~May 2019 · 11 months · monthly snapshotTerminated~May 2019 – ~Jan 2021 · 20 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshotTerminated~Feb 2026 – present · 7 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 6 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. May 2019 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Jun 2018 — May 2019 [monthly]

    Terminated PHASE2

  4. Jul 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jul 2017 [monthly]

    Terminated PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arrowhead Pharmaceuticals
Data source: Arrowhead Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations